why choose us

First received: November 22, 2022

Clinical Trial: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Pancreatic Cancer

Study Type: INTERVENTIONAL


Official Title: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Brief Summary: To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation.The safety and possible effects of adagrasib will also be studied.

Read more